Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients

Pfizer

Status and phase: Withdrawn; Phase 2

Conditions: Kidney Transplantation

Treatments: Drug: CP-690-,550; Drug: Cyclosporine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00556257

A3921037

Details and patient eligibility

About

A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recipient of first time kidney transplant
• Between the ages of 18 and 70 years, inclusive

Exclusion criteria

• Recipient of any non-kidney transplant

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

Treatment Arm 1

Active Comparator group

Description:

Treatment Arm 1 will also receive standard of care medications.

Treatment:

Drug: Cyclosporine

Treatment Arm 2

Experimental group

Description:

Treatment Arm 2 will also receive select standard of care medications.

Treatment:

Drug: CP-690-,550